TRIPLE NEGATIVE BREAST CANCER

This early-phase study tests a new type of vaccine made from a patient's own immune cells. The vaccine is given directly into the spinal fluid to target breast cancer that has spread to the lining of the brain and spinal cord. The main goal is to find the safest dose and see if i…

This early-phase study tests a vaccine called PVX-410, alone or with the immunotherapy drug pembrolizumab, in 20 women with metastatic triple negative breast cancer who have a specific genetic marker (HLA-A2+). The goal is to see if the vaccine safely boosts the immune system to …

This study looks at whether giving precise radiation (SBRT) to tumors that have just started to grow can help people with metastatic triple-negative breast cancer or non-small cell lung cancer live longer without their disease getting worse. About 107 adults are taking part. The …

This study tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) plus chemotherapy in people with triple negative breast cancer. It includes two groups: those with early-stage cancer and those with advanced cancer that has spread. The goal is to see if the…

This phase 3 study tests a new drug, SKB264, against standard treatments for people with advanced triple-negative breast cancer that has not responded to at least two prior therapies. The main goal is to see if SKB264 can delay cancer growth. About 254 participants are being stud…

This study tests whether adding different doses of radiation to a standard chemotherapy and immunotherapy (pembrolizumab) regimen before surgery can improve outcomes for people with lymph node-positive, HER2-negative breast cancer. About 120 participants will receive the combinat…

This study tests a new antibody drug, acasunlimab, in people with advanced solid tumors that have not responded to standard treatments. The first part checks safety and finds the best dose, while the second part tests how well it works alone or with other cancer drugs. About 429 …

This study tests a new drug called FDA018-ADC against standard chemotherapy in 350 people with advanced triple-negative breast cancer that came back after taxane treatment. The goal is to see if the new drug can delay cancer growth and improve survival. Participants are randomly …

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug works by attaching to cancer cells and blocking their growth. About 119 participa…

This study tested a chemotherapy combination (carboplatin and nab-paclitaxel) given before surgery to people with a fast-growing type of breast cancer called triple negative. The goal was to shrink tumors enough so that no cancer remains at the time of surgery. The study included…

This early-stage study tests an experimental pill, ATV-1601, in people with advanced solid tumors (including certain breast, ovarian, and prostate cancers) that have a specific AKT1 gene mutation. The main goals are to check the drug's safety, find the best dose, and see how the …

This study tests whether adding a drug called ipatasertib to standard chemotherapy and immunotherapy helps shrink or eliminate aggressive triple-negative breast tumors before surgery. About 146 women with newly diagnosed, high-risk breast cancer will participate. The main goal is…

This phase 3 trial tests whether the drug sacituzumab govitecan can prevent breast cancer from coming back in people with HER2-negative breast cancer who still have cancer cells after standard chemotherapy before surgery. About 1,300 participants will receive either the new drug …

This study aimed to test a combination of three drugs (zimberelimab, domvanalimab, and sacituzumab govitecan) as a first treatment for people with advanced triple-negative breast cancer that shows a specific marker (PD-L1 positive). The goal was to see if the combo could shrink t…

This study tests a treatment made from a patient's own immune cells (called LN-145) for cancers like ovarian, triple-negative breast, anaplastic thyroid, and bone sarcomas that have not responded to standard therapy or have returned. The cells are taken from the tumor, grown in a…

This phase 3 study tests whether a new combination of drugs (sacituzumab govitecan and pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that has a specific marker (PD-L1). About 443 participants who h…

This study tests a new drug called BNT327, given together with chemotherapy, for people with advanced triple-negative breast cancer that has spread. The goal is to see if the combination is safe and shrinks tumors. About 83 adults will take part, receiving one of two dose levels …

This study looks at whether the number of immune cells in and around a triple-negative breast cancer tumor can help doctors choose the best chemotherapy and immunotherapy before surgery. About 139 women with early-stage breast cancer will receive treatment tailored to their immun…

This early-phase study tests the drug niraparib given together with radiation therapy after surgery for triple negative breast cancer. It includes 21 patients who had residual disease after chemotherapy. The goal is to find the safest dose and see if the combination helps prevent…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy before surgery can help the immune system fight triple-negative breast cancer more effectively. About 15 people with early-stage (stage II or III) triple-negative breast cancer will receive …

This early-phase study tests a new drug (DKY709) alone or with another drug (PDR001) in adults with advanced solid tumors like lung cancer, melanoma, and breast cancer that have not responded to standard treatments. The main goal is to check safety and find the right dose. About …

This phase 3 study compares a new drug, BL-B01D1, to standard chemotherapy in 418 people with advanced triple-negative breast cancer that has stopped responding to taxane chemotherapy. The goal is to see if BL-B01D1 can slow cancer growth and extend survival. Participants receive…

This study tests a combination of three drugs (cisplatin, romidepsin, and nivolumab) in people with advanced triple-negative breast cancer or breast cancer linked to BRCA gene mutations. The goal is to see if the combination can shrink tumors and control the disease. About 51 adu…

This study tests a drug called sacituzumab govitecan against standard chemotherapy in people with advanced triple-negative breast cancer that does not have a protein called PD-L1. The goal is to see if the new drug can delay cancer growth or improve survival. About 623 participan…

This study tests a combination of two drugs, ribociclib and bicalutamide, in people with advanced triple-negative breast cancer that has a specific marker (androgen receptor). The goal is to see if this combo can shrink tumors or stop them from growing. About 37 participants will…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can help eliminate tumors in people with localized triple-negative breast cancer. About 51 women with early-stage, untreated disease will receive the combination, then have …

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This study is for people with triple-negative breast cancer who still have cancer after initial chemotherapy and surgery. It compares the usual follow-up drug (capecitabine) alone versus adding an immunotherapy drug (atezolizumab) to see if the combination helps prevent the cance…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can eliminate all signs of cancer in people with early-stage triple-negative breast cancer before they have surgery. About 31 participants with small tumors (1 to 2.5 cm) that haven't sp…

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to target and attack cancer cells while sparing healthy ones. The study will check if the drug is safe and what dose wor…

This early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…

This study was planned to test two drugs, Ezabenlimab and BI 907828, in people with advanced solid tumors like sarcoma, lung, breast, colorectal, or bile duct cancer. The goal was to see if the combination could control tumor growth for at least 24 weeks. However, the study was w…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy is safe and effective for people with metastatic triple negative breast cancer. About 29 adults with advanced disease that cannot be removed by surgery will receive one of two chemothera…

This study tests whether combining two drugs (niraparib and dostarlimab) with radiation therapy is safe and effective for people with metastatic triple-negative breast cancer that has not responded to immunotherapy or is PD-L1 negative. About 32 adults with this aggressive cancer…

This study tests a new drug called nadunolimab, given together with standard chemotherapy, for people with advanced triple-negative breast cancer. The goal is to see if the combination is safe and can shrink tumors better than chemo alone. About 117 adults with this aggressive ca…

This early-phase study tests an experimental drug called ABBV-400 in about 302 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The main goals are to check safety, side effects, and whether the drug shrinks tumors. Participants receive …

This study tests a new drug called DS-1062a in people with advanced solid tumors, including certain lung and breast cancers that have not responded to standard treatments. It is the first time this drug is being used in humans, and the main goals are to check its safety and find …

This study looks at 15 women with triple-negative breast cancer to see if certain proteins in the blood during radiation therapy can predict if the cancer will come back early. The goal is to find a simple blood test that tells doctors which patients need extra treatment. No new …

This study looks at whether a simple blood test measuring certain proteins can help predict if triple-negative breast cancer will return after treatment. Researchers will follow 90 women with early-stage triple-negative breast cancer, collecting blood samples at key points during…

This study is looking at whether certain blood cell counts and tumor markers can help predict if triple negative breast cancer will come back. Researchers will compare blood test results with tumor samples from 90 women before and after treatment. The goal is to find better ways …

This study looks at how doctors treat advanced or metastatic triple-negative breast cancer in Canada, the UK, France, and Spain. Researchers will collect information from medical records of about 760 patients to understand which tests and treatments are used and how well they wor…